JP2016525121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525121A5 JP2016525121A5 JP2016527137A JP2016527137A JP2016525121A5 JP 2016525121 A5 JP2016525121 A5 JP 2016525121A5 JP 2016527137 A JP2016527137 A JP 2016527137A JP 2016527137 A JP2016527137 A JP 2016527137A JP 2016525121 A5 JP2016525121 A5 JP 2016525121A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- alkoxy
- compound
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 144
- 239000001257 hydrogen Substances 0.000 claims description 144
- 125000000217 alkyl group Chemical group 0.000 claims description 118
- 150000001875 compounds Chemical class 0.000 claims description 99
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 90
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 65
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 64
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 50
- 150000002431 hydrogen Chemical class 0.000 claims description 44
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
- -1 methoxy, substituted ethoxy Chemical group 0.000 claims description 23
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 239000011593 sulfur Substances 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 206010002091 Anaesthesia Diseases 0.000 claims description 8
- 230000037005 anaesthesia Effects 0.000 claims description 8
- 206010039897 Sedation Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000036280 sedation Effects 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 208000005809 status epilepticus Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 0 C[C@](CCC1)(CC2(*)*)[C@@]1[C@](CC1)[C@]2[C@@](C)(CC2(C)C)C1(*)C[C@@]2O Chemical compound C[C@](CCC1)(CC2(*)*)[C@@]1[C@](CC1)[C@]2[C@@](C)(CC2(C)C)C1(*)C[C@@]2O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019106471A JP6974388B2 (ja) | 2013-07-19 | 2019-06-06 | 向神経活性ステロイド、組成物、およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361856592P | 2013-07-19 | 2013-07-19 | |
| US61/856,592 | 2013-07-19 | ||
| PCT/US2014/047246 WO2015010054A2 (en) | 2013-07-19 | 2014-07-18 | Neuroactive steroids, compositions, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019106471A Division JP6974388B2 (ja) | 2013-07-19 | 2019-06-06 | 向神経活性ステロイド、組成物、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525121A JP2016525121A (ja) | 2016-08-22 |
| JP2016525121A5 true JP2016525121A5 (enExample) | 2017-08-31 |
| JP6578277B2 JP6578277B2 (ja) | 2019-09-18 |
Family
ID=52346850
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527137A Active JP6578277B2 (ja) | 2013-07-19 | 2014-07-18 | 向神経活性ステロイド、組成物、およびそれらの使用 |
| JP2019106471A Active JP6974388B2 (ja) | 2013-07-19 | 2019-06-06 | 向神経活性ステロイド、組成物、およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019106471A Active JP6974388B2 (ja) | 2013-07-19 | 2019-06-06 | 向神経活性ステロイド、組成物、およびそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20160152658A1 (enExample) |
| EP (2) | EP3021852B1 (enExample) |
| JP (2) | JP6578277B2 (enExample) |
| CN (1) | CN105555277B (enExample) |
| AU (1) | AU2014290400B2 (enExample) |
| BR (1) | BR112016000975B1 (enExample) |
| CA (2) | CA3199003A1 (enExample) |
| CY (1) | CY1124330T1 (enExample) |
| DK (1) | DK3021852T3 (enExample) |
| ES (1) | ES2864719T3 (enExample) |
| HR (1) | HRP20210610T1 (enExample) |
| HU (1) | HUE053900T2 (enExample) |
| LT (1) | LT3021852T (enExample) |
| PL (1) | PL3021852T3 (enExample) |
| PT (1) | PT3021852T (enExample) |
| RS (1) | RS61733B1 (enExample) |
| RU (1) | RU2754534C2 (enExample) |
| SI (1) | SI3021852T1 (enExample) |
| SM (1) | SMT202100229T1 (enExample) |
| WO (1) | WO2015010054A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| SG10201608148TA (en) | 2012-08-21 | 2016-11-29 | Sage Therapeutics Inc | Methods Of Treating Epilepsy Or Status Epilepticus |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| DK2986624T3 (da) | 2013-04-17 | 2020-06-29 | Sage Therapeutics Inc | Neuroaktive 19-nor-steroider til terapeutisk anvendelse |
| PL3498725T3 (pl) | 2013-04-17 | 2021-11-08 | Sage Therapeutics, Inc. | 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| EP3021852B1 (en) | 2013-07-19 | 2021-01-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
| PE20170925A1 (es) | 2014-10-16 | 2017-07-13 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016164763A1 (en) * | 2015-04-10 | 2016-10-13 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) * | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| CA3279953A1 (en) | 2016-07-11 | 2025-11-29 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP4302764A3 (en) | 2016-07-11 | 2024-06-26 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| BR112019003637A2 (pt) | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN107236015A (zh) * | 2017-06-15 | 2017-10-10 | 甘肃兰药药业有限公司 | 一种醋酸阿比特龙还原杂质及其制备方法 |
| JP2021505608A (ja) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害を処置するためのジュウテリウム化された２１−［４−シアノ−ピラゾール−１−イル］−１９−ノル−プレガン−３．α−オール−２０−オン誘導体 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| BR112021024033A2 (pt) | 2019-05-31 | 2022-02-08 | Sage Therapeutics Inc | Esteroides neuroativos e suas composições |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114828889B (zh) | 2019-12-06 | 2025-02-14 | 马瑞纳斯制药公司 | 用于治疗结节性硬化症的加奈索酮 |
| CN110903339A (zh) * | 2019-12-06 | 2020-03-24 | 南京正济医药研究有限公司 | 一种罗库溴胺中间体5α-甾烷-2-烯-17-酮的制备方法 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| US12410209B2 (en) * | 2021-06-29 | 2025-09-09 | Board Of Regents, The University Of Texas System | Modified glucocorticoids |
| CN114409718A (zh) * | 2021-12-31 | 2022-04-29 | 湖北武当安泰药业有限公司 | 去氢表雄酮催化加氢制备表雄酮的方法 |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| US3365611A (en) | 1965-07-01 | 1968-01-23 | Burroughs Corp | Magnetic core circuit for indicator tube |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| GB1434919A (en) * | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| US3943124A (en) * | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) * | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CA2118938A1 (en) | 1991-09-13 | 1993-04-01 | Kelvin W. Gee | Novel gabaa receptor with steroid binding sites |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| EP0656365B1 (en) * | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| EP0752860B1 (en) * | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| WO1996003421A1 (en) | 1994-07-21 | 1996-02-08 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| AP653A (en) * | 1994-11-23 | 1998-07-21 | Cocensys Inc | Androstane and pregnane series for allosteric modulations of gaba receptor. |
| US5925630A (en) | 1995-06-06 | 1999-07-20 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| IL146230A0 (en) | 1999-04-29 | 2002-07-25 | Purdue Pharma Ltd | 3α-HYDROXY-3β-METHOXYMETHYL-SUBSTITUTED STEROIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| US6717002B2 (en) | 2000-02-18 | 2004-04-06 | Taiho Pharmaceutical Co., Ltd. | Method of producing steroid derivatives |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| US6844456B2 (en) | 2000-11-03 | 2005-01-18 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| JP4719144B2 (ja) | 2003-03-24 | 2011-07-06 | ステリックス リミテッド | ステロイドスルファターゼのインヒビターとしてのエストロゲン誘導体 |
| EP1626980A4 (en) | 2003-05-29 | 2007-07-04 | Univ Washington | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS |
| US20070099880A1 (en) | 2003-11-24 | 2007-05-03 | Blizzard Timothy A | Estrogen receptor modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2005330504B2 (en) | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| SI2168585T1 (sl) | 2005-06-09 | 2012-04-30 | Euro Celtique Sa | Farmacevtski sestavki nevroaktivnega steroida in njihove uporabe |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) * | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| EP2155204B1 (en) | 2007-06-15 | 2016-08-17 | Research Triangle Institute | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ2008434A3 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US20100120733A1 (en) | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| AU2011284606A1 (en) | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
| CN103347525A (zh) | 2010-12-15 | 2013-10-09 | 哈博生物科学公司 | 制备3α-氧取代的甾族化合物的方法及化合物 |
| CZ201181A3 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9457033B2 (en) | 2011-02-15 | 2016-10-04 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| US9388210B2 (en) * | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP5265816B2 (ja) | 2011-03-23 | 2013-08-14 | 悦朗 伊藤 | タンパク質および核酸の超高感度測定法およびキット、並びに新規な酵素基質 |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| EP4245369A3 (en) | 2011-09-08 | 2023-11-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2012323888A1 (en) | 2011-10-14 | 2014-05-29 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| WO2014058736A1 (en) | 2012-10-08 | 2014-04-17 | Washington University | Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| EP2916846B1 (en) | 2012-11-09 | 2025-09-17 | Drawbridge Pharmaceuticals Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP3392260B1 (en) | 2012-12-18 | 2022-09-21 | Washington University | Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| PL3498725T3 (pl) | 2013-04-17 | 2021-11-08 | Sage Therapeutics, Inc. | 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii |
| DK2986624T3 (da) | 2013-04-17 | 2020-06-29 | Sage Therapeutics Inc | Neuroaktive 19-nor-steroider til terapeutisk anvendelse |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| EP3021852B1 (en) | 2013-07-19 | 2021-01-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| CA2949720C (en) | 2014-05-29 | 2025-11-18 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS, THEIR COMPOSITION AND USES |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3188734A4 (en) | 2014-09-02 | 2018-01-10 | The Texas A&M University System | Method of treating organophosphate intoxication |
| ES2808855T3 (es) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Composiciones y métodos para tratar trastornos del SNC |
| PE20170925A1 (es) | 2014-10-16 | 2017-07-13 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos del snc |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| WO2016134301A2 (en) | 2015-02-20 | 2016-08-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CN108350021A (zh) | 2015-09-08 | 2018-07-31 | 视点医疗公司 | 用于治疗眼科疾病的化合物和制剂 |
| WO2017066626A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| TW202400182A (zh) | 2016-03-08 | 2024-01-01 | 美商賽吉醫療公司 | 神經活性類固醇，其組合物及用途 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CA3279953A1 (en) | 2016-07-11 | 2025-11-29 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| EP4302764A3 (en) | 2016-07-11 | 2024-06-26 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| BR112019003637A2 (pt) | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | um esteróide 19-nor c3,3-dissubstituído c21-n-pirazolil cristalino |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| MX2020001732A (es) | 2017-08-31 | 2020-03-20 | Takeda Pharmaceuticals Co | Tratamiento de las afecciones del sistema nervioso central. |
| IL303250A (en) | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
-
2014
- 2014-07-18 EP EP14826212.4A patent/EP3021852B1/en active Active
- 2014-07-18 AU AU2014290400A patent/AU2014290400B2/en active Active
- 2014-07-18 DK DK14826212.4T patent/DK3021852T3/da active
- 2014-07-18 SM SM20210229T patent/SMT202100229T1/it unknown
- 2014-07-18 HU HUE14826212A patent/HUE053900T2/hu unknown
- 2014-07-18 JP JP2016527137A patent/JP6578277B2/ja active Active
- 2014-07-18 RU RU2016105436A patent/RU2754534C2/ru active
- 2014-07-18 RS RS20210493A patent/RS61733B1/sr unknown
- 2014-07-18 CA CA3199003A patent/CA3199003A1/en active Pending
- 2014-07-18 PT PT148262124T patent/PT3021852T/pt unknown
- 2014-07-18 WO PCT/US2014/047246 patent/WO2015010054A2/en not_active Ceased
- 2014-07-18 HR HRP20210610TT patent/HRP20210610T1/hr unknown
- 2014-07-18 BR BR112016000975-4A patent/BR112016000975B1/pt active IP Right Grant
- 2014-07-18 US US14/906,043 patent/US20160152658A1/en not_active Abandoned
- 2014-07-18 PL PL14826212T patent/PL3021852T3/pl unknown
- 2014-07-18 ES ES14826212T patent/ES2864719T3/es active Active
- 2014-07-18 LT LTEP14826212.4T patent/LT3021852T/lt unknown
- 2014-07-18 CN CN201480051239.XA patent/CN105555277B/zh active Active
- 2014-07-18 SI SI201431809T patent/SI3021852T1/sl unknown
- 2014-07-18 EP EP21152393.1A patent/EP3868382A1/en active Pending
- 2014-07-18 CA CA2918735A patent/CA2918735C/en active Active
-
2017
- 2017-09-07 US US15/698,151 patent/US10323059B2/en active Active
-
2019
- 2019-04-24 US US16/393,396 patent/US11046728B2/en active Active
- 2019-06-06 JP JP2019106471A patent/JP6974388B2/ja active Active
-
2021
- 2021-04-07 CY CY20211100299T patent/CY1124330T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525121A5 (enExample) | ||
| RU2016105436A (ru) | Нейроактивные стероиды, композиции и их использование | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2016528301A5 (enExample) | ||
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016531134A5 (enExample) | ||
| JP2013515074A5 (enExample) | ||
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| RU2016110418A (ru) | Нейроактивные стероиды, их композиции и применение | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| JP2018505898A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| RU2015143610A (ru) | Лечение катаплексии | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| AR101177A1 (es) | Inhibidores de la syk | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2016503797A5 (enExample) | ||
| JP2015535247A5 (enExample) | ||
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| IN2014DN05869A (enExample) |